网络首发:2015-12-20,
纸质出版:2015
移动端阅览
半乳糖凝集素-3与β-Catenin在上皮性卵巢癌中的表达和 临床指标及预后关系[J]. 中山大学学报(医学科学版), 2015,36(6).
Expression of Galectin -3 and β -catenin in Epithelial Ovarian Cancer and Their Clinical Significance[J]. Journal of Sun Yat-sen University (Medical Sciences), 2015, 36(6).
摘 要: 【目的】 探讨半乳糖凝集素-3(Galectin-3 Gal-3)和β-Catenin在上皮性卵巢癌组织中的表达情况及临床意义。【方法】 采用免疫组织化学方法,检测77例上皮性卵巢癌患者肿瘤组织中Gal-3和β-Catenin蛋白表达的情况,并分析其与患者临床病理特征、治疗效果及预后的关系。 【结果】 在77例卵巢癌组织中,Gal-3阳性表达率为(70/77)90.9%。β-catenin阳性表达率为(65/77)84.4%。正常卵巢上皮不表达Gal-3和β-Catenin蛋白。Gal-3和β-Catenin的表达常表现为正相关关系,相关系数r = 0.437,P = 0.000。将弱阳性与强阳性合并为阳性后进行统计分析,Gal-3与病理类型相关,β-Catenin与病理类型、是否复发相关,P < 0.05。单因素(Cox回归)分析显示,临床分期(P = 0.019)、复发(P = 0.007)、铂耐药(P = 0.000)及Gal-3表达(P = 0.007)为影响上皮性卵巢癌患者术后总体生存(OS)的因素。多因素分析显示,铂类耐药(HR = 0.233,P = 0.001)与Gal-3表达(HR = 2.325,P = 0.036)与预后明显相关。【结论】 Gal-3和β-Catenin可能与上皮性卵巢癌的发生发展有关,并可作为上皮性卵巢癌预后不良的预测指标,Gal-3可能通过β-Catenin激活经典的Wnt通路,在在上皮性卵巢癌中,发生、发展中起重要作用。
Abstract: 【Objective】 To evaluate the expression of galectin -3 and β -catenin in epithelial ovarian cancer tissues and their correlation with clinicopathological and survival variables. 【Method】 Seventy -seven patients with epithelial ovarian cancers(EOC) were selected, and their tumor tissues were collected. The expression of galectin -3 and β -catenin were tested by immunohistochemical analysis. Then the correlation of the expression of Gal -3 and β -catenin with the clinicopathological parameters, treatment outcomes and survival of these patients were evaluated. 【Result】 Galectin -3 protein, which was mainly cytoplasmic in location, was observed in a majority (70/77, 90.9%) of the EOC but not in normal ovarian tissues (P < 0.05). β -Catenin protein, which was mainly cytoplasmic and membranous in location, was observed in a majority (65/77, 84.4%) of the EOC but not in normal ovarian tissues (P < 0.05). Combine weak staining with strong staining, Gal -3 expression in EOC correlated with histology, while β -Catenin expression correlated with histology and recurrence. Spearman bivariate correlation test show a positive correlation between the expression of Gal -3 and β -Catenin in EOC,r = 0.437,P = 0.000. Univariate analysis revealed that stage(P = 0.019), recurrence(P = 0.007), platinum resistance(P = 0.000) and high Gal -3 expression(P = 0.007) predicted overall survival (OS). Further multivariate analysis showed platinum resistance(HR = 0.233 P = 0.001)and Gal -3 expression(HR = 2.325, P = 0.036)was independent prognostic factor for OS for these patients. 【Conclusions】 Gal -3 may activate Wnt pathway by mediate β -Catenin in the cytoplasm in EOC.Gal -3 may become a prognosis factor of recurrence, platinum resistance and poor outcome. New drugs which targeting Gal -3 are expected to become effective therapies for platinum -resistant EOC.
0
浏览量
223
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
